186 related articles for article (PubMed ID: 19028360)
1. Anti-resorptives in the management of osteoporosis.
Miller PD
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):849-68. PubMed ID: 19028360
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: how do they work?
Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic targets for osteoporosis: beyond denosumab.
Lim V; Clarke BL
Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
[TBL] [Abstract][Full Text] [Related]
4. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
Seeman E
Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
[TBL] [Abstract][Full Text] [Related]
5. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
Gasser JA
Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
[TBL] [Abstract][Full Text] [Related]
6. Monitoring pharmacological therapy for osteoporosis.
Lewiecki EM
Rev Endocr Metab Disord; 2010 Dec; 11(4):261-73. PubMed ID: 20143165
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of osteoporotic fracture by pharmaceutical interventions].
Nakamura T
Clin Calcium; 2006 Dec; 16(12):1961-67. PubMed ID: 17142925
[TBL] [Abstract][Full Text] [Related]
8. Anti-resorptive therapies for osteoporosis.
Reid IR
Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
[TBL] [Abstract][Full Text] [Related]
9. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
10. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
Lyritis GP; Georgoulas T; Zafeiris CP
Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
[TBL] [Abstract][Full Text] [Related]
11. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
Shiraki M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
[No Abstract] [Full Text] [Related]
12. Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Geoffroy V; Paschalis EP; Libouban H; Blouin S; Ostertag A; Chappard D; Cros M; Phipps R; de Vernejoul MC
Calcif Tissue Int; 2011 Jun; 88(6):464-75. PubMed ID: 21455736
[TBL] [Abstract][Full Text] [Related]
13. The treatment of osteoporosis. Antiresorptive therapy.
Miller PD
Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
[TBL] [Abstract][Full Text] [Related]
14. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
Kastelan D; Giljevic Z; Kraljevic I; Korsic M
Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological diversity among drugs that inhibit bone resorption.
Russell RG
Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
